Free Trial

Palisade Bio (PALI) Competitors

Palisade Bio logo
$0.76 0.00 (-0.59%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$0.76 +0.01 (+0.73%)
As of 07:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PALI vs. ME, RLMD, TRIB, SYBX, ERNA, MRKR, CLDI, RLYB, HOTH, and NXTC

Should you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include 23andMe (ME), Relmada Therapeutics (RLMD), Trinity Biotech (TRIB), Synlogic (SYBX), Eterna Therapeutics (ERNA), Marker Therapeutics (MRKR), Calidi Biotherapeutics (CLDI), Rallybio (RLYB), Hoth Therapeutics (HOTH), and NextCure (NXTC). These companies are all part of the "pharmaceutical products" industry.

Palisade Bio vs.

23andMe (NASDAQ:ME) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, community ranking, institutional ownership and media sentiment.

23andMe has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.

Palisade Bio has lower revenue, but higher earnings than 23andMe. Palisade Bio is trading at a lower price-to-earnings ratio than 23andMe, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
23andMe$208.78M0.06-$666.70M-$15.45-0.03
Palisade Bio$250K14.51-$12.30M-$6.80-0.11

In the previous week, 23andMe had 15 more articles in the media than Palisade Bio. MarketBeat recorded 19 mentions for 23andMe and 4 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.75 beat 23andMe's score of 0.04 indicating that Palisade Bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
23andMe
0 Very Positive mention(s)
3 Positive mention(s)
15 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Palisade Bio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

23andMe received 1 more outperform votes than Palisade Bio when rated by MarketBeat users. However, 52.38% of users gave Palisade Bio an outperform vote while only 46.15% of users gave 23andMe an outperform vote.

CompanyUnderperformOutperform
23andMeOutperform Votes
12
46.15%
Underperform Votes
14
53.85%
Palisade BioOutperform Votes
11
52.38%
Underperform Votes
10
47.62%

Palisade Bio has a net margin of 0.00% compared to 23andMe's net margin of -183.39%. Palisade Bio's return on equity of -148.51% beat 23andMe's return on equity.

Company Net Margins Return on Equity Return on Assets
23andMe-183.39% -170.07% -62.13%
Palisade Bio N/A -148.51%-115.16%

36.1% of 23andMe shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 26.3% of 23andMe shares are owned by company insiders. Comparatively, 3.3% of Palisade Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Palisade Bio has a consensus price target of $12.00, indicating a potential upside of 1,486.25%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts clearly believe Palisade Bio is more favorable than 23andMe.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
23andMe
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Palisade Bio
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Palisade Bio beats 23andMe on 11 of the 18 factors compared between the two stocks.

Get Palisade Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PALI vs. The Competition

MetricPalisade BioBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$3.63M$2.93B$5.33B$8.39B
Dividend YieldN/A1.64%5.21%4.10%
P/E Ratio-0.0531.1826.7519.70
Price / Sales14.51398.78392.41121.79
Price / CashN/A168.6838.2534.62
Price / Book0.043.236.774.50
Net Income-$12.30M-$72.35M$3.23B$248.22M
7 Day Performance10.15%2.49%0.43%-0.80%
1 Month Performance6.91%2.45%9.07%11.52%
1 Year Performance-85.34%-24.98%18.59%8.99%

Palisade Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PALI
Palisade Bio
2.9468 of 5 stars
$0.76
-0.6%
$12.00
+1,486.3%
-85.3%$3.63M$250,000.00-0.0510Gap Down
ME
23andMe
N/A$0.50
-35.3%
N/A-95.2%$13.36M$208.78M-0.03770Gap Down
High Trading Volume
RLMD
Relmada Therapeutics
4.4296 of 5 stars
$0.40
-4.6%
$4.25
+962.5%
-80.1%$13.28MN/A-0.1410Positive News
Insider Trade
Gap Down
TRIB
Trinity Biotech
0.7203 of 5 stars
$0.73
-3.1%
N/A-52.6%$13.18M$59.13M-0.32480
SYBX
Synlogic
N/A$1.13
+0.9%
N/A-30.4%$13.10M$8,000.00-0.2780Upcoming Earnings
High Trading Volume
ERNA
Eterna Therapeutics
0.7588 of 5 stars
$0.21
+5.2%
N/A-88.5%$13.10M$582,000.00-0.0310Gap Up
MRKR
Marker Therapeutics
4.0913 of 5 stars
$1.14
-1.7%
$13.17
+1,055.0%
-71.3%$12.90M$6.59M-0.9560Positive News
CLDI
Calidi Biotherapeutics
1.9155 of 5 stars
$0.44
-3.3%
$15.00
+3,279.9%
N/A$12.63M$50,000.000.0038
RLYB
Rallybio
1.8674 of 5 stars
$0.30
+2.7%
$10.00
+3,223.4%
-80.7%$12.52M$636,000.00-0.1940
HOTH
Hoth Therapeutics
2.7217 of 5 stars
$0.93
-2.5%
$4.00
+330.5%
-30.0%$12.24MN/A-0.704Analyst Downgrade
Gap Down
NXTC
NextCure
3.947 of 5 stars
$0.43
-2.6%
$3.50
+705.9%
-69.3%$12.18MN/A-0.2190Positive News
Gap Down

Related Companies and Tools


This page (NASDAQ:PALI) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners